Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

November 2019; 6 (6) EditorialOpen Access

Pembrolizumab as a treatment for PML?

Waiting for Godot

Renaud A. Du Pasquier
First published October 9, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000629
Renaud A. Du Pasquier
From the Division of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne, University of Lausanne, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Pembrolizumab as a treatment for PML?
Waiting for Godot
Renaud A. Du Pasquier
Neurol Neuroimmunol Neuroinflamm Nov 2019, 6 (6) e629; DOI: 10.1212/NXI.0000000000000629

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
936

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Progressive multifocal leukoencephalopathy (PML) is an infrequent but severe disease of the brain. In the setting of immunosuppression, the polyomavirus JC (JCV) may reactivate, migrate to the brain, infect oligodendrocytes, and to a lesser extent astrocytes, and cause demyelinating lesions. As there are currently no available anti-JCV therapy, the only treatment consists of restoring immunity. Whereas restoring immunity is feasible in patients with AIDS-PML (by giving antiretroviral therapy) or in natalizumab-treated patients with MS (by stopping administration of natalizumab), achieving this in patients with hemopathies or with an intrinsically defective immune response is less straightforward. Consequently, the prognosis is particularly grim in the latter patients.

Initially designed to boost tumor cell-specific T-cell responses, anti-program cell death-1 (PD-1) monoclonal antibodies (mAbs) have recently been proposed for the treatment of PML.1,–,3 Indeed, in a first wave of publications in the April issue of the NEJM, 10 patients with PML who received anti-PD-1 mAb were reported, including 7 who showed a mild to marked improvement, 1 who was stable before treatment, and 2 who had a frank worsening.

In the current issue of Neurology® Neuroimmunology & Neuroinflammation, 2 case reports showing absolutely no benefit of pembrolizumab mitigate this initial enthusiasm.4,5 The case reported by Küpper et al. is particularly intriguing since, a priori, if anyone should have been a good candidate for this drug, it was this patient. He had primary immunodeficiency syndrome, was young (42 years old), had never received immunosuppressive drugs, and, at the time of PML onset, had only a minor clinical deficit, limited MRI lesions, and a low viral load in his CSF.4 He actually had the lowest number of JCV copies/mL (35) in the CSF of all 12 reported cases of PML treated with anti-PD-1 so far (table). Moreover, pembrolizumab was started early in the course of the disease, and the patient received 5 doses, whereas the majority of the other patients had received fewer doses. And yet, the patient showed a relentless evolution and fatal outcome. It seems that pembrolizumab may even have had a deleterious effect because the JCV viral load in the CSF began to rise after the beginning of pembrolizumab infusion (figure 1B of Ref. 4).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table

Summary of the clinical and virologic data of the 12 patients with PML who have been treated with anti–program cell death-1

As with the 10 previously reported cases of PML treated with anti-PD-1, the 2 patients reported in this issue had a clear decrease in their PD-1+ T-cell number. Thus, one has to look for other parameters, which could predict the prognosis of PML in patients treated with anti-PD-1 mAbs. As highlighted in table, there is no obvious clinical or paraclinical characteristic that would predict the outcome of PML under pembrolizumab.

In this context, the second case report may provide some element of response. Pawlitzki et al.5 describe a 37-year-old patient who presented with several immunosuppressive conditions, developed PML, and received 2 infusions of pembrolizumab, but died 1 month after the second infusion. Unlike the first case, this second patient had an extremely high JCV viral load in the CSF (>2.5 × 106 copies/mL) at the time of PML diagnosis, suggesting that JCV had already extensively infected the brain (table).

In an attempt to understand the reasons why the patient did not respond to pembrolizumab, the authors analyzed the population of progenitor-exhausted vs terminally exhausted memory T cells. Of interest, they found that their patient had fewer progenitor- and more terminally exhausted T cells than another pembrolizumab-treated patient with PML who showed a favorable outcome.2 These data are interesting, as they suggest that only a subset of PD-1+ T cells has the capacity to revert from exhaustion and become active again. Thus, patients with PML who are deprived of progenitor-exhausted cells would be those who do not respond to pembrolizumab. As advocated by Koralnik in his NEJM editorial,6 the authors also looked at the JCV-specific T-cell response in the 2 patients, the one with a favorable outcome2 and the one with a progressive course of PML.5 They gather from this experiment that JCV-specific CD4+ T cells might be more instrumental than CD8+ T ones in keeping JCV on check. However, considering the very low percentage of cells in both populations and the minimal differences between the responder and the progressive patient, these data should be taken with caution.

Finally, should we offer pembrolizumab to patients with PML or not? This drug is certainly not the long-awaited panacea for PML. However, considering the absence of treatment for this deadly disease, proposing this drug to patients for whom there is no other way to boost the cellular immune response seems, at least for the time being, reasonable.

Study funding

No targeted funding reported.

Disclosure

R.A. Du Pasquier served on the scientific advisory board for Merck, Celgene, and Sanofi; received travel funding and/or speaker honoraria from Celgene and Roche; and received research support from the Swiss National Foundation and Swiss Society for Multiple Sclerosis. Go to Neurology.org/NN for full disclosures.

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • Clinical/Scientific Notes, page e627

  • Clinical/Scientific Notes, page e628

  • Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Cortese I,
    2. Muranski P,
    3. Enose-Akahata Y, et al
    . Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 2019;380:1597–1605.
    OpenUrl
  2. 2.↵
    1. Rauer S,
    2. Marks R,
    3. Urbach H, et al
    . Treatment of progressive multifocal leukoencephalopathy with pembrolizumab. N Engl J Med 2019;380:1676–1677.
    OpenUrl
  3. 3.↵
    1. Walter O,
    2. Treiner E,
    3. Bonneville F, et al
    ; Immune Checkpoint Inhibitors in PML Study Group. Treatment of progressive multifocal Leukoencephalopathy with nivolumab. N Engl J Med 2019;380:1674–1676.
    OpenUrl
  4. 4.↵
    1. Küpper C,
    2. Heinrich J,
    3. Kamm K,
    4. Bücklein V,
    5. Rothenfusser S,
    6. Straube A
    , Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency. Neurol Neuroimmunol Neuroinflamm 2019;6:e628. doi: 10.1212/NXI.0000000000000628.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Pawlitzki M,
    2. Schneider-Hohendorf T,
    3. Rolfes L, et al
    . Ineffective treatment of PML with pembrolizumab: exhausted memory T-cell subsets as a clue? Neurol Neuroimmunol Neuroinflamm 2019;6:e627. doi: 10.1212/NXI.0000000000000627.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Koralnik IJ
    . Can immune checkpoint inhibitors keep JC virus in check? N Engl J Med 2019;380:1667–1668.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis

Dr. Robert Pitceathly and Dr. William Macken

► Watch

Related Articles

  • Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency
  • Ineffective treatment of PML with pembrolizumabExhausted memory T-cell subsets as a clue?

Topics Discussed

  • Autoimmune diseases
  • Viral infections

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathy
    Evelyn Dubois, Christoph Ruschil, Felix Bischof et al.
    Neurology - Neuroimmunology Neuroinflammation, October 29, 2015
  • Article
    Progressive multifocal leukoencephalopathy after fingolimod treatment
    Joseph R. Berger, Bruce A. Cree, Benjamin Greenberg et al.
    Neurology, April 18, 2018
  • Article
    Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy
    Franziska Hopfner, Nora Möhn, Britta Eiz-Vesper et al.
    Neurology: Neuroimmunology & Neuroinflammation, May 17, 2021
  • Articles
    Determinants of survival in progressive multifocal leukoencephalopathy
    A. Marzocchetti, T. Tompkins, D. B. Clifford et al.
    Neurology, November 09, 2009
Neurology - Neuroimmunology Neuroinflammation: 10 (3)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise